Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Ampio Pharmaceuticals, Inc. (AMPE)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.1784-0.0226 (-11.24%)
At close: 04:00PM EDT
0.1702 -0.01 (-4.60%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2010
Open0.1960
Bid0.1620 x 1100
Ask0.1725 x 1000
Day's Range0.1784 - 0.2070
52 Week Range0.1500 - 1.8300
Volume22,183,227
Avg. Volume4,010,285
Market Cap40.52M
Beta (5Y Monthly)1.54
PE Ratio (TTM)N/A
EPS (TTM)-0.0790
Earnings DateMar 01, 2022 - Mar 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.50
  • PR Newswire

    Ampio Pharmaceuticals' CEO Mike Martino Issues Letter to Stockholders

    Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today released the following letter to stockholders from its Chief Executive Officer, Mike Martino.

  • Benzinga

    Ampio's Independent Committee Launches Investigation Related To AP-013 Trial

    Ampio Pharmaceuticals Inc's (NYSE: AMPE) independent special Committee of the Ampio Board of Directors has started an internal investigation regarding Ampio's AP-013 trial with the assistance of independent legal counsel. FDA has communicated to Ampio that it does not consider data from AP-013 to be sufficient to demonstrate efficacy as a second pivotal trial for Ampion. Further analysis suggests that data from AP-013 will not be sufficient to support regulatory approval in the US or other count

  • PR Newswire

    Ampio Pharmaceuticals Reports First-Quarter Financial Results

    Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today reported financial results for the first quarter ended March 31, 2022.

Advertisement
Advertisement